Nataliya Andreychuk shares perspectives on pharma marketing and content operations, including how teams can reuse approved content, improve content activation, and apply AI in their workflows. She also hosts Pharma Talks conversations with people working in pharma.
They are most useful for pharma content operations, content activation, reuse, and AI workflow discussions.
Best for
This fits a pharma marketing technology webinar with them presenting on content supply chain activation.
Not for
This does not fit consumer financial services short-form video promoting cashback with discount codes.
Key takeaways
Pharma has solved content creation but not content activation.
Reuse is blocked by formats and weak governance, not by a shortage of content.
Most of what marketing calls personalisation is segmentation.
Check first: Confirm audience demographics, sponsorship format, and past webinar attendance data.
Main ideas
Pharma has solved content creation but not content activation · Experience creates assumptions, so benchmark the data before redesigning · Reuse is blocked by formats and weak governance, not by a shortage of content
Nataliya Andreychuk writes and speaks about pharma marketing, content operations and the practical changes needed to make approved content useful.
In her posts, she challenges teams to look beyond producing more material: approved content can go unused, legacy assets can be hard to adapt, and disconnected teams can offer customers an inconsistent experience.
Andreychuk also hosts Pharma Talks conversations, including discussions of content operations and public trust.
Andreychuk connects visible marketing problems to the workflows and systems behind them.
She argues that segmentation is not the same as personalisation when marketing, sales and customer success act on different signals, and that content stored in PDFs is difficult to reuse without rebuilding it.
Her practical emphasis is on fixing the underlying structure: one conversation recommends starting modular-content work with a claims library; another argues that teams should assess existing approved content before commissioning more.
She also brings the same systems focus to AI, urging pharma leaders to rethink how work gets done rather than just speed up existing processes.
In a post about a 2026 report, she says its benchmarks draw on workflow data from 20 pharma and life sciences companies—a useful example of her emphasis on checking assumptions against operational evidence.
Nataliya Andreychuk writes and speaks about pharma content operations, and one argument runs through most of it: the industry has become good at producing and approving content but not at getting it used.
Read more
The recurring proposals are to audit and reuse what already exists, to benchmark content operations against real workflow data rather than experience and assumption, and to treat AI as a change to operating models rather than a way to work faster. A separate line of argument attacks marketing's use of the word personalisation, and the Pharma Talks podcast, which Andreychuk hosts, extends the same thinking into trust, pricing transparency and commercial leadership through conversations with guests.
Pharma has solved content creation but not content activation
Andreychuk argues that producing more approved assets will not produce more engagement until content, compliance and field readiness run as one loop.
Read more
The first move is not a new batch of content but an honest look at what already exists, followed by matching the right asset to the right person at the moment of need.
In a talk at the 16th Annual SFE & Digital Marketing Pharma Summit, Andreychuk cited a figure that 80% of approved pharma content is rarely or never used, after it has already been reviewed by medical, legal and regulatory teams and paid for, and called the situation a content graveyard. The recommendation to the room was to go back to content that already exists before asking for the next batch.
The same problem is revisited later in a Pharma Talks conversation about whether the content graveyard persists and why storing content modules is not the same as reusing them.
Experience creates assumptions, so benchmark the data before redesigning
Andreychuk's argument is that transformation often fails because it transforms the wrong thing.
Read more
Experience is valuable but also generates assumptions, and looking at large volumes of real workflow records can make those assumptions look different. Published benchmarks and a maturity framework give teams a way to compare their own operations before redesigning them.
The State of Pharma Content Supply Chain 2026 report is described as built from thousands of workflow data points across 20 pharma and life sciences companies in Europe, North America and APAC, and is offered as a reality check: compare, question, and start transformation from an honest picture of the present.
Reuse is blocked by formats and weak governance, not by a shortage of content
Andreychuk argues that pharma has more content than it knows what to do with, yet much of it is trapped in formats that are hard to reuse.
Read more
Localising or adapting a legacy document means rebuilding it. The fix is structural: break content into reusable elements while preserving the structure and meaning that make those elements valuable, and start from simple foundations rather than complex modular programmes.
A Q3 eWizard release is described as making it easier to break existing content into reusable elements, shifting content from something stored to something reused. In a Pharma Talks conversation, guest Rasmus Kalms and Andreychuk discuss the gap between storing modules and actually reusing them, and the advice to start with the claims library instead of overcomplicating the approach.
AI raises an operating-model question, not just a speed question
Andreychuk accepts that pharma has learned to use AI to speed work up, then argues the harder question is what has to change in roles, review steps and handoffs around it.
Read more
The future commercial leader is framed as a builder, an orchestrator or an AI manager, and AI demonstrations are presented as a way to move approved messaging into channel-ready content through localisation and compliance steps.
On the main stage at NEXT Pharma Summit, Andreychuk argued that pharma does not need more leaders who simply know how to use AI; it needs leaders who rethink how work gets done. The closing summit post repeats the point after interest in the live eVa AI demo.
The argument sharpens across the summit: the opening post raises the operating-model question and the closing post states it as the main takeaway from the event.
Most of what marketing calls personalisation is segmentation
Andreychuk draws a line between putting a large group of people into a segment and personalising a message to an individual, and says segmentation is not wrong until teams treat it as sufficient.
Read more
The deeper failure described is internal: marketing, sales and customer success each act on a different signal while the customer experiences one brand.
A post linking to an article for pharmaphorum says that placing 10,000 people in a segment and sending them a message based on assumed common ground personalises nothing, and points readers to the full article on why pharma brands keep getting personalisation wrong and what silos have to do with it. The article text itself is not part of the reviewed material, so the detail behind the silo examples is not available here.
Trust in pharma is tied to access, affordability and transparent pricing
This argument is carried mainly by a guest conversation rather than by Andreychuk alone.
Read more
The framing is a trust paradox: pharma develops life-changing medicines, but scientific breakthroughs alone do not guarantee public trust while patients still face barriers to access, affordability and understanding their treatment options.
In a Pharma Talks episode, guest Raphael Blum, an oncology commercial leader who has worked across global pharma and now advises early-stage companies, discusses communicating the value of innovation and pricing more transparently, where AI can support commercial teams, and how leadership sets priorities. The post ties the episode to October's breast cancer awareness attention and the wider challenges facing people affected by cancer.
Answers the single question a newcomer is most likely to have: what is the actual problem in pharma content operations?
Read more
It states the core argument in one number and stays on it.
Nataliya Andreychuk opens with a figure: 80% of approved pharma content is rarely or never used — reviewed by medical, legal and regulatory teams, paid for, then buried.
The post comes from a talk at the 16th Annual SFE & Digital Marketing Pharma Summit, and the argument is that teams have solved making content but not activating it.
More assets will not produce more engagement, in this account, until content, compliance and field readiness run as one loop.
The practical suggestion is to go back to content that already exists before asking for a next batch, and the post notes demos of eVa and Kheiron as ways clients approach it in practice.
For brands planning a campaign
This is the clearest statement of the content activation thesis and the most direct basis for a webinar on activating approved content rather than producing more of it.
A newcomer who wants to know whether the content-supply-chain claims rest on data rather than opinion should start here.
Andreychuk argues that decisions made from experience carry assumptions, and that looking at large volumes of real workflow data can unsettle them.
The post introduces a State of Pharma Content Supply Chain 2026 report built on thousands of workflow data points from 20 pharma and life sciences companies across Europe, North America and APAC, with data, benchmarks and a maturity framework.
The closing advice is to use the report as a reality check on your own content operations — compare, question, and start transformation from an honest picture of the present.
For brands planning a campaign
Useful as the research hook for a webinar: the underlying report gives the session a benchmark and maturity model rather than an opinion.
Shows the conversation format behind the argument and extends it past the opening number into storage, reuse and governance.
Read more
It is the best entry point to the podcast work.
This post introduces the first part of a Pharma Talks conversation with Rasmus Kalms.
The topics named are pharma's content graveyard, the difference between storing content modules and actually reusing them, and the point that better AI depends first on better content structure, governance and workflows.
The two also revisit modular content — a concept many companies invested in, sometimes with little to show for it — and the recurring advice to start simply, with the claims library.
Links to the episode are given for several podcast platforms.
For brands planning a campaign
Demonstrates the hosted-conversation format and a guest pairing; useful if the webinar is planned as a discussion rather than a solo presentation.
Answers a concrete mechanism question: why is existing content so hard to reuse?
Read more
The post names the blocker and the fix without abstraction.
Andreychuk points to legacy content locked in PDF as a format problem: localising it means rebuilding it, and adapting it for another channel means starting again.
The post describes the direction of a Q3 eWizard release, which makes it easier to break existing content into reusable elements while preserving the structure and meaning that give those elements value.
The framing is a shift from content you store to content you can reuse, presented as a step toward content operations that scale.
For brands planning a campaign
A product-adjacent example that still leads with the workflow problem; relevant if the webinar needs one concrete demonstration of reuse in practice.
Shows a published byline outside LinkedIn and a distinct argument.
Read more
A newcomer can judge whether the thinking holds up in a longer form than a post.
The post argues that most of what marketing calls personalisation is segmentation: putting 10,000 people into a segment and sending them a message based on assumed common ground personalises nothing.
It says the deeper problem is behind the scenes, where marketing, sales and customer success each act on a different signal while the customer experiences one brand.
Andreychuk links to an article for pharmaphorum that sets out why pharma brands keep getting personalisation wrong, what silos have to do with it, and what needs to change.
For brands planning a campaign
A citable byline and a cross-functional framing; useful for widening a webinar beyond content operations into how teams share data about the customer.
Shows how the podcast handles commercial and reputational subjects rather than content operations alone, which helps a reader judge the range of the work.
Read more
Andreychuk frames a trust paradox: pharma develops life-changing medicines, but breakthroughs alone do not guarantee trust while patients still face barriers to access, affordability, and understanding their treatment options.
The post introduces a Pharma Talks episode with Raphael Blum, described as an experienced oncology commercial leader who has worked across global pharma and now advises early-stage companies.
The conversation covers communicating the value of innovation and pricing more transparently, where AI can support commercial teams, and how leadership sets priorities.
The post also notes October's additional attention to breast cancer awareness as a moment to reflect on treatment access.
For brands planning a campaign
Broader thought-leadership territory than content activation; a possible secondary angle if the session is framed around trust and communication rather than supply chain.
Answers what the person argues on a main stage in front of a large industry audience, as distinct from what they publish in posts.
Read more
Andreychuk describes a main-stage talk at the NEXT Pharma Summit with a plain argument: pharma has learned to use AI to speed things up, and now needs to rethink the operating models around it.
The post also covers a panel discussion on what the future commercial leader in pharma will look like — a builder, an orchestrator, or an AI manager — with named panellists bringing different experiences and angles.
Space is given to the Pharma Talks studio recording conversations from the event floor.
For brands planning a campaign
Evidence of main-stage speaking experience and of an operating-model angle on AI; useful for pitching a session that pairs technology with organisation design.
Benchmarking the pharma content supply chain with data1
Personalisation versus segmentation, and internal silos1
Trust, access, and affordability in pharma communication1
Content activation, not just content creation
Nataliya Andreychuk argues that pharma has solved the problem of making content but not the problem of using it.
Read more
One post cites a figure that 80% of approved pharma content is rarely or never used, after it has already been reviewed by MLR and paid for, and describes that as a content graveyard.
The recommended first step is not a new batch of assets but a review of what already exists, followed by matching content to the right person at the right moment at the speed of need.
The argument is that content, compliance, and field readiness have to run as one loop before more assets produce more engagement.
Conference talk supported by a single benchmark statistic, with product demos used to show how existing content could be activated.
For brands planning a campaign
A webinar framed around activation and measurement of existing assets rather than new content production fits the position Nataliya Andreychuk already argues publicly, and the 80% figure gives a concrete hook for the invitation and opening segment.
Benchmarking the pharma content supply chain with data
A 2026 State of Pharma Content Supply Chain report is presented as the output of thousands of workflow data points from 20 pharma and life sciences companies across Europe, North America, and APAC.
Read more
The post's stated point is that experience is valuable but also creates assumptions, and that looking at large numbers of real workflow records can make some assumptions look different. The report is offered as data, benchmarks, and a maturity framework that teams can use as a reality check on their own content operations before redesigning them.
Published research report summarised in a short post, with the dataset described by sample size, sectors, and regions.
For brands planning a campaign
A data-led angle works here: the report, its sample of 20 companies, and its maturity framework can anchor a webinar around benchmarking rather than opinion, with audience teams comparing their own numbers against the published set.
Nataliya Andreychuk describes pharma content as more plentiful than teams know what to do with, while much of it is trapped in PDFs that are hard to reuse.
Read more
Localising or reformatting such content means rebuilding it, which is presented as a real obstacle to scaling content operations.
A Q3 product release is described as making it easier to break existing content into reusable elements while preserving structure and meaning, shifting content from something stored to something reused.
A Pharma Talks conversation with Rasmus Kalms covers the gap between storing modules and actually reusing them, and recommends starting with the claims library rather than overcomplicating the approach.
Product release framing combined with a podcast conversation on workflows and governance.
For brands planning a campaign
This is the most operational topic in the set and supports a practical webinar segment: walk through reuse of an existing approved asset, the claims-library starting point, and the workflow steps between storage and reuse.
The recurring argument is that pharma has learned to use AI to speed things up and now needs to rethink the operating models around it.
Read more
One post from NEXT Pharma Summit poses the future commercial leader as a builder, an orchestrator, or an AI manager. A live demo of eVa AI is described as turning approved messaging into content for different channels and helping teams work through localisation, compliance, and the steps in between, and the closing summit post repeats that pharma needs leaders who rethink how work gets done rather than leaders who simply know how to use AI.
Conference stage talk plus a live product demonstration, with audience questions taken in the room.
For brands planning a campaign
A change-management framing rather than a tool demo suits this position: the webinar can ask what has to change in roles, review steps, and handoffs for AI-assisted content to reach the field.
Personalisation versus segmentation, and internal silos
In a post linking to an article for pharmaphorum, Nataliya Andreychuk calls personalisation one of the biggest lies in marketing and draws a line between placing 10,000 people in a segment and personalising a message to an individual.
Read more
The post says segmentation is not inherently wrong, but treating it as sufficient is. The described failure sits behind the scenes: marketing, sales, and customer success each work from different signals while the customer experiences one brand.
The argument is summarised in the post and attributed to a linked article; the full article text is not part of the reviewed material, so the detail behind the silo examples is not available here.
For brands planning a campaign
This topic gives a deliberately provocative opening for a webinar and pairs well with the content supply chain theme, since both trace the same problem back to disconnected teams and systems.
Trust, access, and affordability in pharma communication
A Pharma Talks episode with oncology commercial leader Raphael Blum is framed around a trust paradox: pharma develops life-changing medicines, but scientific breakthroughs alone do not guarantee public trust when patients still face barriers to access, affordability, and understanding their treatment options.
Read more
The conversation covers communicating the value of innovation and pricing more transparently, where AI can support commercial teams, and how leadership sets priorities. The post also ties the episode to breast cancer awareness in October and the wider challenges facing people affected by cancer.
For brands planning a campaign
For a reputation-sensitive webinar, this gives a tested line of argument about transparency in pricing and innovation communication, plus a named conversation partner and episode the audience can listen to beforehand.
Nataliya Andreychuk hosts Pharma Talks conversations, including episodes recorded in a studio set up at NEXT Pharma Summit, and posts about preparing questions, capturing perspectives from the community, and publishing the results.
Read more
Episodes are pointed to on YouTube, Apple Podcasts, Amazon Music, and Spotify. Conference posts cover main-stage remarks, panel discussions with named speakers, and takeaway themes from the event, with promises of further episodes and reflections after the summit.
On-site recording studio at a pharma commercial conference, with interviews distributed as a podcast across four platforms.
For brands planning a campaign
The interview format is already established, so a thought-leadership webinar can be positioned as one more conversation in an existing series rather than a new format, with promo assets tying into the same podcast channels.
Nataliya Andreychuk's posts show them working as part of Viseven: they speak in company terms ('our services and solutions', 'our new Q3 eWizard release'), demo eVa AI, and promote the State of Pharma Content Supply Chain 2026 report, presenting these as work done with pharma clients.
Read more
The same posts document a contributed article for pharmaphorum, main-stage speaking at NEXT Pharma Summit, a talk at the SFE & Digital Marketing Pharma Summit run by Allan Lloyds, and Pharma Talks, the interview podcast they host. No post discloses a sponsorship, affiliate arrangement, or paid partnership, and none states a job title.
Viseven
Employment
Posts speak as part of the company — 'our services and solutions', 'the Viseven team', 'our new Q3 eWizard release' — and present eVa AI, Kheiron, and eWizard demos and the State of Pharma Content Supply Chain 2026 report as work Viseven does with pharma clients.
Interview podcast hosted by Andreychuk; posts describe recording conversations in the Pharma Talks studio at NEXT Pharma Summit and new episodes with guests, including a discussion of pharma's unused content.
Read more
The posts do not say who owns or produces the show.
Industry event where Andreychuk spoke on the main stage about rethinking operating models around AI and ran a Pharma Talks recording studio; posts recap the two days and the future-commercial-leader discussion.
Organiser of the 16th Annual SFE & Digital Marketing Pharma Summit, where Andreychuk spoke about pharma's content graveyard — '80% of approved pharma content is rarely or never used' — and showed eVa and Kheiron demos.
Pharma marketing publication that ran Andreychuk's article on why pharma brands get personalisation wrong, what silos have to do with it, and what needs to change.
Nataliya Andreychuk's work is easiest to follow through Pharma Talks, the interview podcast that runs through most of these posts, where the recurring subject is how pharma gets content used rather than merely approved.
Read more
Conference talks and summit posts are the other main route in: the 2026 content supply chain report, the modular-content and claims-library argument, and the position that AI changes operating models rather than only speeding work up. For a reader who wants the ideas without the podcast, the posts themselves carry the argument in short form, with links out to episodes and articles.
Pharma content supply chainContent activation and reuseModular content and claims librariesPharmaceutical marketing and commercial operationsPersonalisation versus segmentationAI in pharma marketing teamsPodcast hosting and interviewsConference talks and moderationPharma marketing technologyContent operations and governancePharma commercial and brand leadersPharma and life sciences marketers
Olivier Chateau
Both work on how pharmaceutical and health brands communicate with patients and consumers, and both argue that transparency and patient understanding should shape the message rather than fine print or mass broadcast.
Read more
Both also use a specific regulatory or disclosure moment as the hook for a practical argument.
Chateau's public material is built around direct-to-consumer pharma advertising and patient-community experience, including FDA warning letters and the changing adequate-provision rule, while Andreychuk's centre of gravity is the internal content supply chain: reuse, review steps, and the operating model behind approved assets.
Both critique how marketing is actually practised and both use a well-known campaign as a worked example to show where the discipline breaks down.
Read more
Both also give readers a repeatable decision rule or diagnostic rather than a single opinion: Dietrich runs a campaign through a paid/earned/shared/owned diagnostic and sets out when paid media should be funded.
Dietrich writes across communications and PR for many industries and teaches through the PESO Model framework published through a newsletter, while Andreychuk stays inside pharma commercial content, with the content graveyard, modular content, and pharma-specific governance as the running case.
Both argue that AI adoption in marketing stalls on foundations rather than on the tools, and both draw on survey or benchmark data from practitioners to make that case: asset readiness, systems and operating models on one side, workflow data points and a maturity framework on the other.
Read more
Both also package the finding as a downloadable report.
Vignieri's evidence and audience sit with paid media teams across sectors, and the posts are short survey summaries, while Andreychuk's datasets and examples are drawn from pharma and life sciences content operations, with more emphasis on review and compliance steps between an approved claim and a delivered asset.
For a thought-leadership webinar aimed at pharma teams working on content supply chain activation, Nataliya Andreychuk's audience is a plausible but unmeasured match.
Read more
Her posting is aimed squarely at that world: selected examples from the reviewed material include commentary on reused and "graveyard" pharma content, modular content and claims libraries, the State of Pharma Content Supply Chain 2026 report, an article for pharmaphorum on why personalisation fails in pharma, and episode promotion for the Pharma Talks podcast, including a conversation with an oncology commercial leader and one on pharma content reuse.
The posts also show her speaking and recording at pharma commercial events (NEXT Pharma Summit and the SFE & Digital Marketing Pharma Summit), which is where this kind of audience is typically gathered.
That establishes the appeal of her content to pharma marketing and commercial readers; it does not establish who actually follows her.
The only measured audience figure supplied is a LinkedIn follower count of 12,866 observed on 8 October 2026.
Nothing in the evidence measures followers' employers, job function, seniority, geography, age, or gender, and no audience survey or platform demographic export was supplied.
A LinkedIn follower count tells a buyer how large a reachable pool exists, not how many are the pharma content, medical, legal or commercial decision-makers the webinar needs.
Before confirming a placement on audience grounds, ask for a recent audience report covering follower demographics for the past six to twelve months and any audience survey data on job function and seniority, and, because the brief is a webinar, ask for registration and attendance lists from any previous webinar or the equivalent event sign-up data — those answer whether the reachable audience converts into the right room.
If no such figures exist, treat the reachable audience size as the only confirmed number and plan measurement of the webinar itself.
The reviewed posts document no partnership or sponsorship offer, so no formats are listed here.
Read more
What they do show is Nataliya Andreychuk speaking at and reporting from industry events, hosting the Pharma Talks podcast with guests such as Raphael Blum and Rasmus Kalms, and presenting the products of the company she represents — eVa AI, eWizard, and the State of Pharma Content Supply Chain 2026 report.
Those are her own commercial activities and employer products, not a published menu a brand can buy into, and the material contains no sponsor policy, deliverables list, pricing, or named inquiry route.
For the webinar brief, treat partnership terms as an open question: ask directly about available format, what she would deliver, who handles production and compliance review, and how compensation is handled before building the plan around her.
This is an absence of documentation in the material reviewed, not evidence that she declines sponsorship work.
Brief: a pharma marketing technology company wants to run a thought-leadership webinar on pharma content supply chain activation, with Nataliya Andreychuk as the presenter or host.
Read more
This is a strong fit on subject matter, because the webinar brief is close to a position they already argue in public.
The clearest example is a post recounting a talk at the 16th Annual SFE & Digital Marketing Pharma Summit: 80% of approved pharma content is rarely or never used, reviewed by medical, legal and regulatory teams, paid for, then buried.
The same argument repeats across the reviewed material — teams have solved making content, not activating it, and more assets will not produce more engagement until content, compliance and field readiness run as one loop.
A second piece of supporting material is the State of Pharma Content Supply Chain 2026 report, described as thousands of workflow data points from 20 pharma and life sciences companies across Europe, North America and APAC, with benchmarks and a maturity framework.
That gives a webinar a data spine rather than a string of opinions.
The reuse angle is operational enough to demonstrate: legacy content locked in PDF, where localising means rebuilding and reformatting means starting again, and the advice to start simply with the claims library rather than overcomplicating modular content.
Format fit is also established.
Nataliya Andreychuk hosts Pharma Talks, including a conversation with Rasmus Kalms on content reuse and governance and one with oncology commercial leader Raphael Blum, and has spoken on the main stage at NEXT Pharma Summit.
A hosted, interview-led session is therefore a format they already run, not a new one, and the eVa AI demonstration described after the summit shows they are comfortable giving a live product demonstration inside an event.
Three things to settle before committing.
First, there is no documented partnership offer: the reviewed posts contain no sponsor policy, deliverables list, pricing, or inquiry route.
Terms, production responsibilities and compensation have to be agreed directly.
Second, audience composition is unmeasured.
The only confirmed figure is a LinkedIn follower count of 12,866, with nothing showing how many of those are the content, medical, legal or commercial decision-makers a pharma content webinar needs, so the organiser should assume it is supplying its own list and ask for registration and attendance data from any previous session.
Third, there is a vendor-alignment point a competing marketing technology buyer should raise early rather than after booking: the reviewed material shows Nataliya Andreychuk promoting employer products including eVa AI and eWizard, so clarify which topics and product comparisons are in scope and how any overlap with their own platform is handled.
When to choose a specialist
Brief: a consumer financial services brand wants a creator to produce short-form video promoting a cashback account, paid on a performance basis against app sign-ups, with an exclusive category clause and a discount code.
Read more
This does not fit the documented evidence.
Nothing in the reviewed material shows consumer-facing content, short-form video, performance-based promotion, discount or referral mechanics, or any published rate card, sponsorship format or inquiry route.
The body of work is directed at pharma and life sciences marketing, commercial and content operations professionals: conference talks, a 2026 content supply chain report, a byline for pharmaphorum, and hosted Pharma Talks episodes about content reuse, claims libraries and AI in commercial workflows.
A cashback account offer sits outside that audience and outside anything the person has been shown to work on.
The audience question compounds it.
A consumer financial services buyer needs evidence that viewers actually make sign-up decisions, and the only measured audience number available is a LinkedIn follower count of 12,866.
There is no audience survey, no platform demographic export, and no evidence about followers' employers, job function, seniority, geography or income.
A reachable pool of followers is not a consumer acquisition channel.
The absence of a documented sponsorship offer is not a disqualifier on its own, and it should not be read as proof that paid work is declined.
It does mean the buyer would be pricing the whole arrangement from scratch, with no evidence of past brand work, disclosures or performance reporting to judge.
If a financial services buyer still wants to test the association, the realistic ask is a written thought-leadership contribution about trust and transparency in financial communications — a subject they have covered in pharma terms, including a conversation on pricing transparency and public trust — not a paid product endorsement, and it should be scoped and priced separately from the consumer acquisition campaign.
A worked campaign example
Worked campaign angle: a 45-minute thought-leadership webinar for a pharma marketing technology company, titled around the gap between approved content and used content — for example, "The 80% problem: activating the content you have already approved."
Premise.
Take the audience past content production as the bottleneck.
Use the popular starting number — 80% of approved pharma content is rarely or never used after regulatory review and payment — as the opening premise, then spend the rest of the session on the operational steps that change it: finding reusable elements inside existing assets, starting from a claims library, and treating compliance and field readiness as part of the same loop rather than a gate at the end.
Format and roles.
Nataliya Andreychuk presents or hosts, in the interview-led style already used on Pharma Talks, with one guest from a pharma commercial or content operations role.
The Kalms conversation on content reuse is the working model: one external voice, a narrow problem, and disagreement kept in the room.
The pharmaphorum article on personalisation versus segmentation supplies an optional segment if the host wants to widen the conversation from content operations to how marketing, sales and customer success each act on different signals.
Running order.
First ten minutes: the activation problem, stated with the 80% figure and the reason content earns burial.
Next fifteen: a live walkthrough of reuse — take an approved asset, break it into elements that keep their structure and meaning, and show what happens when the same source has to be localised or reformatted.
Use the demo material from the NEXT Pharma Summit as the reference point, and keep the demonstration workflow-focused rather than a product tour.
Next ten: the claims library as the starting point, and why modular content programmes have produced little for companies that started with tooling instead of structure.
Final ten: questions, drawn from the room rather than pre-screened, since the reviewed material shows questions from the room are where sharper challenges surface.
Assets.
Publish the State of Pharma Content Supply Chain 2026 report, or the benchmark tables from it, as a downloadable handout so attendees can compare their own numbers.
Cut one short clip of the reuse walkthrough for promotion and one for follow-up.
Point attendees to the relevant Pharma Talks episode in the follow-up email, which gives a second touch without new production.
Measurement.
Ask the organiser for registration and attendance figures, attendance duration, question volume, and handoff to sales conversations.
Because follower composition is unmeasured, treat engagement on her own channels as reach, not as evidence of the right attendees, and judge the session on who registered and who stayed.
Before booking, settle four things in writing: whether the arrangement is a paid engagement or a joint session; who writes and clears the content, and whether it needs medical, legal and regulatory review on either side; how any overlap between the host company's platform and eVa AI or eWizard is handled publicly; and who owns the recording and the clips afterwards.
Choose Olivier Chateau if the webinar buyer wants the session to move from internal content supply chain mechanics toward the patient-facing side of pharma advertising: DTC regulation, truth in advertising, transparency, and how patient communities already set the standard for honest treatment information.
Read more
Chateau's posts cover the FDA Commissioner's DTC National remarks — pharma TV ads are protected under the First Amendment, but the FDA sent more than 150 warning letters on misleading drug ads in one year, up from zero in 2024, and the agency wants to replace the current adequate-provision rule with critical information placed in the ad itself.
Chateau also led a DTC National session on reimagining consumer engagement through innovation and transparency, and writes from 15+ years building patient communities in digital health.
That gives the organiser a speaker who can debate the new rules of engagement for DTC media strategy with firsthand patient-community context.
The tradeoff is that Chateau's evidence is about consumer and patient-facing pharma advertising and engagement, not the operational content supply chain the original brief centres on: modular content, claims libraries, legacy PDF content, MLR review loops, and reuse across channels.
A buyer whose audience is content operations, medical/legal/regulatory, or field readiness teams would get less practical detail on activation workflows than from Nataliya Andreychuk.
The two posts do not show a hosted webinar format, a content supply chain report, or a product demonstration, so the organiser would need to reshape the session around DTC media strategy and patient trust rather than content activation.
Choose Gini Dietrich if the buyer wants a communications-strategy framework applied to pharma campaign activation rather than a content-operations walkthrough.
Read more
Dietrich's posts use the PESO Model to diagnose why a well-liked pharma ad failed to drive action: the Novartis Super Bowl ad was remembered and won the Pharma Lions Grand Prix at Cannes, but the quiz, locator, clinical guidance, website and email list did not connect, and it ranked 75th for what viewers actually did next.
Dietrich also gives a paid media decision rule — only put budget behind a message when it is clear in one sentence, backed by social proof, has an owned destination answering obvious questions, and has already shown signal in shared media.
For a webinar on activation, that is a ready-made argument for treating paid, earned, shared and owned as one system, and for not using paid media to manufacture trust.
The tradeoff is that Dietrich's evidence is a cross-industry PR and communications lens, not a pharma content supply chain one.
The posts do not discuss MLR review workflows, modular content, claims libraries, localisation, or field readiness in the operational detail the original brief requires.
A pharma marketing technology buyer wanting to show how to activate approved content inside regulated workflows would get a strong external challenge on measurement and channel integration, but not the same depth on the internal content pipeline.
Dietrich also brings a widely known framework and newsletter promotion, which can shift the session toward communications strategy and away from the buyer's product category.
Choose Matthew Vignieri if the buyer wants the webinar to focus on AI readiness for paid media teams and the foundations that must exist before agentic AI is useful.
Read more
Vignieri's posts draw on a Skai survey of 332 paid media practitioners: teams are far more confident in their people than in the data, systems and operating models that AI agents depend on, and the biggest obstacles are asset readiness, systems and interoperability, and operating model.
The posts set out five priorities for making an organisation ready to get the most from AI.
For a pharma marketing technology company, that gives a data-backed frame for the argument that AI in content and campaign work depends on structure, governance and workflow — close to the content supply chain activation problem, but arrived at from the media team's readiness side.
The tradeoff is that Vignieri's evidence is about paid media teams and agentic AI readiness generally, not pharma-specific content supply chain activation.
The posts do not cover MLR review, pharma content graveyards, modular content reuse, claims libraries, or localisation.
A buyer who needs the session to speak directly to pharma content, compliance and commercial operations would have to translate the readiness findings into that context.
Vignieri also writes from a media technology platform perspective, so the buyer should clarify any overlap between that platform and their own before booking, just as they would with the original candidate.
This profile draws on ten posts published from Nataliya Andreychuk's LinkedIn account, reviewed in full, plus the accepted sections on ideas, brands and businesses, similar creators and campaign fit.
The material centres on a 2026 reporting and conference cycle: the State of Pharma Content Supply Chain 2026 report, a Q3 product release note, two Pharma Talks episode announcements, a personalisation article for pharmaphorum, and posts from NEXT Pharma Summit in October 2026.
The account itself was observed on 8 October 2026.
Similar-creator comparisons rest on two posts each from Olivier Chateau, Gini Dietrich and Matthew Vignieri.
Gaps: podcast episode audio and full transcripts, the full pharmaphorum article text, the report itself, any sponsor page, rate card or inquiry route, and any audience demographic, survey or event attendance data were not available.
Audience reach rests on a single follower figure, and campaign fit is reasoned from published content and formats rather than from documented past brand partnerships.
Recent engagement
Across their last 8 LinkedIn posts, the median post got 28 reactions and 1 comments. Checked 2026-11-02.
